Search results
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?
Simply Wall St. via Yahoo Finance· 20 hours ago(NASDAQ:REGN) as an investment opportunity by taking the forecast future cash flows of the company...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron ...
NBC 10 - FOX 14 Monroe· 13 hours agoPomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (
Leonard S. Schleifer Sells 25,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock
ETF DAILY NEWS· 6 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) CEO Leonard S. Schleifer sold 25,000 shares of Regeneron< ...
RBC maintains $1,185 target on Regeneron amid court case By Investing.com
Investing.com· 6 days agoOn Friday, RBC Capital maintained its Outperform rating on Regeneron (NASDAQ:REGN) Pharmaceuticals (...
Regeneron CEO Leonard Schleifer sells over $22 million in company stock By Investing.com
Investing.com· 6 days agoIn a recent transaction, Leonard S. Schleifer, the CEO and Co-Chair of Regeneron (NASDAQ:REGN) ...
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Motley Fool via Yahoo Finance· 7 days agoDrugmakers outside the biosimilar or generic-medicine market must constantly innovate to be...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...
Benzinga· 3 days agoDupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International...
The Yuma Sun· 6 days agoTARRYTOWN, N.Y. and WASHINGTON, May 17, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoNEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zymeworks Inc. (
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
InvestorPlace· 3 days agoIn addition, while the market has been robust – with the Dow Jones Industrial Average breaching the...
